Skip to main content
Aelis Farma logo

Aelis Farma — Investor Relations & Filings

Ticker · AELIS ISIN · FR0014007ZB4 LEI · 8945008D5R6WV7EXRN47 PA Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2025-04-29 Report Publication Anno…
Country FR France
Listing PA AELIS

About Aelis Farma

https://www.aelisfarma.com

Aelis Farma is a clinical-stage biopharmaceutical company that discovers and develops treatments for brain and central nervous system (CNS) disorders. The company has created a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary mechanism is designed to selectively inhibit the pathological signaling of the CB1 receptor, which is implicated in various brain diseases, while preserving its normal physiological functions and avoiding adverse effects associated with previous CB1-targeting drugs. The company's lead drug candidate, AEF0117, is in development for the treatment of Cannabis Use Disorder (CUD). Its second candidate, AEF0217, is being investigated for the treatment of cognitive deficits, including those associated with Down syndrome.

Recent filings

Filing Released Lang Actions
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Report Publication Announcement Classification · 98% confidence The document is explicitly titled "Mise à disposition du Document d'Enregistrement Universel 2024" (Making available of the 2024 Universal Registration Document). It states that the Universal Registration Document (Document d'Enregistrement Universel) has been filed with the AMF (Autorité des marchés financiers) and includes the annual financial report, auditor reports, and ESG information. Since the text is an announcement stating that a comprehensive report (the Universal Registration Document, which often encompasses elements of a 10-K or a detailed annual filing) has been made available, and it is short (under 5,000 characters), it fits the definition of a Report Publication Announcement (RPA) rather than the full report itself (like 10-K or AR). If the document were the full Universal Registration Document, it would likely be classified as 10-K or AR, but this is clearly a press release announcing its availability.
2025-04-29 French
Annual financial and audit reports / Terms of availability of the annual financial report
Report Publication Announcement Classification · 98% confidence The document explicitly announces the "Availability of the 2024 Universal Registration Document (URD)" which was filed with the French Financial Markets Authority (AMF). It details that the URD includes the annual financial report and statutory auditor's reports. The document itself is a press release announcing the availability of this comprehensive report, rather than the report itself. According to Rule 2 (The "MENU VS MEAL" Rule), a short announcement stating that a report has been published or is available points towards a Report Publication Announcement (RPA). While the URD contains elements of an Annual Report (10-K) and Audit Report (AR), the document provided is the announcement of its release, making RPA the most accurate classification for this specific filing type.
2025-04-29 English
DEU 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-04-28 French
Inside Information / News release on accounts, results
Earnings Release Classification · 100% confidence The document is explicitly titled 'Aelis Farma reports its 2024 annual financial results and confirms its 2025 outlook' and contains detailed, audited (or soon to be audited, as the certification report is being issued) financial statements for the year ended December 31, 2024, including an income statement, cash flow statement, and balance sheet details. This structure and content are characteristic of a comprehensive annual financial report. Although it is presented as a 'Press release' and includes operational highlights, the core content is the full-year financial performance review, which aligns best with the Annual Report (10-K) definition, even if it is a preliminary release of the data contained within the formal 10-K filing. Since it contains the full financial tables and management discussion ('Full-year results 2024 (IFRS)'), it is classified as the report itself rather than just an announcement of the report (RPA). FY 2024
2025-04-01 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 100% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces the "résultats financiers annuels 2024" (annual financial results 2024) along with operational highlights and future outlook. It contains summarized IFRS financial tables (Compte de résultat simplifié, Flux de trésorerie) and management commentary. This structure—a press release summarizing annual financial performance—is characteristic of an Earnings Release (ER), which typically precedes or accompanies the full 10-K filing. Since it provides the key financial highlights and commentary immediately following the fiscal year-end, it fits the definition of an Earnings Release (ER) better than the comprehensive 10-K, which is a formal regulatory filing. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR). The document is dated April 1, 2025, reporting on the year ended December 31, 2024, which is typical for an ER. FY 2024
2025-04-01 French
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is explicitly labeled as a "Press Release" and details the final analysis results of a Phase 2B clinical trial for a drug candidate (AEF0117) treating Cannabis Use Disorder (CUD). It presents key efficacy and safety data, compares results to previous trials, and outlines future development plans. This content structure—announcing significant clinical trial results via a press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a detailed announcement of clinical trial results rather than a comprehensive periodic financial report (10-K or IR), and it is not a transcript (CT) or a formal investor presentation (IP), the most fitting category is Earnings Release (ER), as clinical trial updates often accompany or substitute for quarterly earnings announcements in biotech/pharma, focusing on operational/scientific milestones. Given the document length and content, it is the primary announcement of results, not just a notice of publication (RPA). Q1 2025
2025-03-26 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.